Bisphosphonates are a class of drugs that slow bone loss by blocking the cells responsible for breaking down bone tissue. They are the most widely prescribed medications for osteoporosis and have been in clinical use for decades. By preserving bone density, they significantly reduce the risk of fractures in the spine, hip, and other sites.
How Bisphosphonates Work
Your bones are constantly being remodeled. Specialized cells called osteoclasts break down old bone, while other cells build new bone in its place. In osteoporosis and similar conditions, breakdown outpaces rebuilding, and bones gradually become thinner and more fragile.
Bisphosphonates work by binding tightly to a mineral in bone called hydroxyapatite. This binding is extremely specific, which is why the drugs concentrate in bone tissue rather than affecting other organs. Once attached to bone surfaces, they interfere with osteoclasts by disrupting a key enzyme these cells need to function. Without that enzyme, osteoclasts detach from the bone surface and stop dissolving it. The result is that your body retains more mineral, and bone mass is maintained or even increases over time.
Conditions They Treat
The most common reason doctors prescribe bisphosphonates is osteoporosis, particularly in postmenopausal women and in men over 50. They’re also used to prevent bone loss in people taking long-term corticosteroids, which are known to weaken bones as a side effect.
Beyond osteoporosis, bisphosphonates treat Paget’s disease of the bone (a condition where bones grow abnormally large and weak), dangerously high calcium levels caused by cancer, and bone damage from cancers that have spread to the skeleton. In children and adults with osteogenesis imperfecta, a genetic disorder that causes extremely fragile bones, bisphosphonates are sometimes used off-label.
Types and How They’re Taken
Several bisphosphonates are available in the United States, and they differ mainly in how they’re administered and how often you take them.
Oral bisphosphonates include alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Depending on the specific drug and dose, these are taken daily, weekly, or monthly. Weekly dosing with alendronate or risedronate is the most common outpatient regimen. Monthly oral ibandronate became an option in 2005, and monthly risedronate was approved in 2008.
Intravenous (IV) bisphosphonates include pamidronate (Aredia) and zoledronic acid (Reclast or Zometa). Ibandronate also comes in an IV form given every three months. Zoledronic acid is given as a single infusion once a year for osteoporosis, making it the least frequent dosing option available.
Taking Oral Bisphosphonates Correctly
Oral bisphosphonates are notoriously finicky about how you take them. Food, coffee, tea, juice, and even mineral water all reduce how much of the drug your body absorbs. The standard instructions are to take the pill first thing in the morning on a completely empty stomach, swallowed whole with a full glass (6 to 8 ounces) of plain water. Do not crush or chew it, as this can irritate the throat.
After swallowing, you need to stay upright, either standing or sitting, for at least 30 minutes. Lying down during that window allows the tablet to linger in the esophagus, which can cause irritation or ulcers. You also need to wait at least 30 minutes before eating, drinking anything other than plain water, or taking other medications. People who cannot sit or stand upright for that long, or who have difficulty swallowing, are generally not candidates for oral bisphosphonates. IV formulations offer an alternative in those cases.
How Well They Reduce Fractures
The fracture protection from bisphosphonates is substantial. Alendronate, risedronate, ibandronate, and zoledronic acid all reduce the risk of spinal fractures by 60 to 70% within the first year of treatment. For hip fractures, alendronate, risedronate, and zoledronic acid lower risk by 40 to 50%. Non-vertebral fractures overall drop by 20 to 30% with these three drugs. Ibandronate has not demonstrated the same hip and non-vertebral fracture protection, which is one reason it’s prescribed less often.
Rare but Serious Side Effects
The two side effects that get the most attention are osteonecrosis of the jaw (where a section of jawbone loses its blood supply and begins to deteriorate) and atypical femoral fractures (unusual breaks in the thighbone). Both are rare, but the risk increases the longer you stay on treatment.
For osteoporosis patients, the incidence of jaw osteonecrosis is roughly 0.001%, or about 4 cases per 100,000 patient-years. Cancer patients receiving higher and more frequent bisphosphonate doses face a higher rate, around 0.4%. Atypical femoral fractures occur at about 2 per 100,000 patient-years after two years of treatment, but that number rises to 78 per 100,000 patient-years after eight years. This escalating risk is a major reason doctors consider pausing treatment after several years.
More common, everyday side effects of the oral forms include heartburn, nausea, and irritation of the esophagus. These are usually manageable by following the dosing instructions carefully. IV bisphosphonates can cause flu-like symptoms (fever, muscle aches, fatigue) for a day or two after infusion, particularly after the first dose.
Who Should Not Take Them
All bisphosphonates carry warnings or contraindications for people with severe kidney impairment, generally defined as a creatinine clearance below 30 to 35 mL/min. Because the kidneys are responsible for clearing these drugs from the body, poor kidney function raises the risk of toxicity. Your doctor will typically check kidney function before prescribing one.
How Long Treatment Lasts
Unlike many medications you take indefinitely, bisphosphonate therapy is often reassessed after a set period. The drugs accumulate in bone and continue to release slowly even after you stop taking them, which means their protective effects don’t vanish immediately. This creates the possibility of a “drug holiday,” a planned break from treatment.
Guidelines vary depending on fracture risk. For people at low risk, a drug holiday may be reasonable after 3 to 5 years. For moderate-risk patients, 5 to 10 years of treatment is typical before pausing. For high-risk patients (those with prior fractures, very low bone density, or conditions like long-term steroid use), treatment may continue for up to 10 years before a break is considered. The specific bisphosphonate matters too: data support considering a break from zoledronic acid after 3 years, while alendronate and risedronate holidays are typically considered after 5 years.
During a drug holiday, bone density is monitored periodically. If it begins to decline significantly or a new fracture occurs, treatment is restarted. The decision to pause or continue is highly individual and depends on your bone density scores, fracture history, and overall health profile.